CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation

Prostate Cancer Clinical Trial

Official title:

A Phase I Single-Arm Open Label Dose-Escalation Study of CivaSheet With Radical Prostatectomy With or Without Adjuvant External Beam Radiation Therapy in Patients With High Risk Prostate Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03657108
• Other study ID #: GCO 16-1314
• Secondary ID: PD 16-03067
• Status: Terminated
• Phase: N/A
• Start date: March 27, 2018
• Est. completion date: February 1, 2023

Study information

• Verified date: February 2024
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A phase I single-arm open label dose escalation study to evaluate the maximum tolerated dose (MTD) and safety of Civasheet® with radical prostatectomy (RP) and adjuvant external beam radiation therapy (EBRT) in a 3+3 dose escalation design among participants with high risk prostate cancer (PCa).

Description:

Using preoperative MRI imaging to identify areas suspicious of local advancement in addition to identifying areas with a higher likelihood of a positive margin during RP due to the presence of high risk features, Civasheet® and its inherently flexible structure allow the sheet to be directly implanted on areas suspicious for local advancement and positive surgical margins for direct application of radiation to these areas. The custom, single planar layer, integrative gold shielding of Civasheet® also allows radiation to be provided unidirectionally to allow healthy tissue (i.e., bladder, rectum) to be shielded from radiation; possibly affording a lower rate of gastrointestinal (GI) and genitourinary (GU) toxicity and adverse events. During EBRT, radiation especially for high risk PCa is provided at high rates to the entire prostatic bed with the seminal vesicles, pelvic lymph nodes and a surrounding margin often targeted to eliminate positive margins and cancer from locally advanced areas in which the cancer may have spread (i.e., seminal vesicles, bladder neck). These high rates of radiation often damage surrounding tissue and result in rectal and bladder complications in addition to urethral strictures among other adverse complications. Since Civasheet® will provide radiation to the prostatic bed, a lower dose of EBRT will be used to treat the prostatic bed and potentially lower adverse bladder and rectal effects compared to RP + RT at 60 Gy. 103 Pd seeds of Civasheet® also illuminate on imaging. Therefore placing Civasheet® based on pre-operative identification of areas suspicious for local advancement and areas of likely positive surgical margins during RP will allow for targeted EBRT to the locally advanced areas. Since EBRT can be targeted using Civasheet®, a lower and more direct dose of radiation during EBRT may be used to treat local advancement and positive surgical margins which will potentially reduce toxicity and complications associated with higher doses of radiation.

The above properties are likely to facilitate improved cancer control with more direct and local application of radiation to areas of local advancement surrounding the prostate. These features are also likely to facilitate a reduced complication and toxicity profile since Civasheet® allows EBRT to be applied more accurately and at a lower dose and also the unidirectional radiation applied directly by Civasheet® protects surrounding healthy tissue from receiving radiation.No other studies have attempted to use Civasheet® to improve PCa control and reduce toxicity and complications associated with radiation for participants with high-risk prostate cancer. The investigators anticipate that implanting Civasheet® on areas suspicious for local advancement and positive margins based on pre-operative MRI findings and identification of high risk features in addition to relying on the illumination provided by Civasheet® for targeted adjuvant EBRT will provide a safer complication profile and eventually provide evidence for superior cancer control, lower toxicity and less adverse events than EBRT+ RP alone in a future randomized controlled trial. The investigators therefore propose a phase I single-arm open label dose escalation study to evaluate the MTD and safety of Civasheet® with RP and adjuvant EBRT in a 3+3 dose escalation design among participants with high risk PCa.With this study, the investigators to better understand the MTD, safety and toxicity profile of Civasheet® in the setting of RP + adjuvant EBRT in the treatment of high-risk PCa.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: February 1, 2023
• Est. primary completion date: December 20, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any subject with National Comprehensive Cancer Network (NCCN) very high or high risk adenocarcinoma of the prostate defined as =T3a, Gleason score = 8, or PSA > 20 who is eligible for RP (open or robotic) with adjuvant EBRT as an initial treatment option.

• Any subject with NCCN Intermediate Risk adenocarcinoma of the prostate defined as T2b-T2c, Gleason score 7, or PSA 10-20 who is eligible for RP (open or robotic) with adjuvant EBRT as an initial treatment option and at least one of the following adverse features present in pre-operative imaging: seminal vesicle infiltration (SVI), extracapsular extension (ECE), N1 disease.

• Subject must have had a pre-operative MRI or must obtain a pre-operative MRI to be eligible for participation in this study.

• Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

• Any subject who has undergone prior radiation to the pelvis.

• Subjects presenting with distant metastases.

• On any investigational drug(s), androgen deprivation therapy or therapeutic device(s) within 30 days preceding screening.

• Currently taking immunosuppressants, or with poorly controlled diabetes (HbA1c >8).

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Radiation:
• Civasheet 60 Gy
implantable proposed doses of Civasheet are 60 Gy
• Civasheet 75 Gy
implantable proposed doses of Civasheet are 75 Gy
• Adjuvant external beam radiation therapy
45 Gy in 25 fractions

Locations

Country	Name	City	State
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Mount Sinai West	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Participants With Acute Radiation Toxicity	Number of participants with Acute (occurring within 90 days) radiation toxicity using the Radiation Therapy Oncology Group (RTOG) Acute Toxicity Scale and Late Radiation Morbidity scales; including Grade 4-5 hematuria, fistula formation, proctitis or death.	3 months
Other	Number of Participants With Late Radiation Toxicity	Number of participants with Late (occurring after 90 days) radiation toxicity using the Radiation Therapy Oncology Group (RTOG) Acute Toxicity Scale and Late Radiation Morbidity scales; including Grade 4-5 hematuria, fistula formation, proctitis or death.	after 90 days, up to 4 years 10 months
Other	Number of Radiation Adverse Event(s)	National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0); 5 Grades where Grade 1 is the better outcome and Grade 5 is the worse outcome	4 years 10 months
Primary	Maximum Tolerable Dose (MTD)	MTD is defined as the highest dose of the Civasheet® not yielding unacceptable toxicity. Specifically if > 33 % of subjects experience dose limiting toxicity (DLT) at any dose level, the dose level below that level will be considered the MTD.	90 days
Secondary	Number of Surgical Complications	Number of surgical major complications (major complications defined as Clavien=3.): intraoperative, post operative - acute (< 90 days) and late (18 months).; Grade III - Requiring surgical, endoscopic or radiological intervention; Grade IV - Life-threatening complication (including central nervous system (CNS) complications) requiring intensive care (IC/ICU)-management; Grade V - Death of a patient	intraoperative, postoperative - acute (< 90 days) and late (18 months)
Secondary	Number of Participants With Biochemical Recurrence (BCR)	Number of participants with Biochemical recurrence (BCR) at 6-month follow-up after EBRT. BCR was defined as a post-prostatectomy serum prostate-specific antigen (PSA) level greater than 0.2 nanograms per milliliter (ng/mL).	6-month follow-up after EBRT
Secondary	Number of Participants With Erectile Dysfunction	Number of participants with Erectile Dysfunction at least 6 months after EBRT	6 months after EBRT
Secondary	Number of Participants With PSA Persistence	Number of participants with PSA persistence which is defined as PSA persistently greater than 0.2 ng/mL after surgery.	40 months
Secondary	Number of Participants With Urinary Incontinence	Number of Participants with Urinary Incontinence at least 6 months after EBRT	at least 6 months after EBRT, up to 40 months